Joseph W Kim
Yale University · Yale University Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Joseph W Kim as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:10 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06100705 · Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPCYale University · recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph2NCT03047213 · Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 MutationsNational Cancer Institute (NCI) · active not recruiting · Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma, Metastatic Urothelial Carcinoma · principal investigator
- Ph2NCT02893917 · Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerNational Cancer Institute (NCI) · active not recruiting · Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation · principal investigator
- Ph2NCT02498613 · A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNational Cancer Institute (NCI) · active not recruiting · Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA016359 · NCI · YALE UNIVERSITY · fiscal years 2025 to 2026 · $231,156 awarded in 2026Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026Named on NCT02498613
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:10 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Metal versus plastic stents for drainage of malignant biliary obstruction before primary surgical resection.Gastrointest Endosc · 201660 citationsRCR 3.3
- A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer.Int J Radiat Oncol Biol Phys · 200442 citationsRCR 1.1
- Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.Proteomics · 201238 citationsRCR 1.1
- 25 citationsRCR 2.7
- Intraoperative Radiotherapy for Resectable Pancreatic Cancer Using a Low-Energy X-Ray Source: Postoperative Complications and Early Outcomes.Yonsei Med J · 20228 citationsRCR 0.6